Should You Sell Your GlaxoSmithKline (GSK) Position Before its Too Late?

Nelson Capital Management, an investment management firm, published its second-quarter 2021 investor letter – a copy of which can be downloaded here. In the letter, the fund discussed their economic overview, their asset transactions, tax updates, featured equity, and a special topic about the housing bubble. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.

In the Q2 2021 investor letter of Nelson Capital Management, the fund mentioned GlaxoSmithKline plc (NYSE: GSK) and discussed its stance on the firm. GlaxoSmithKline plc is a San Diego, California-based pharmaceutical industry company with a $105.5 billion market capitalization. GSK delivered a 14.05% return since the beginning of the year, while its 12-month returns are up by 3.50%. The stock closed at $41.97 per share on August 13, 2021.

Here is what Nelson Capital Management has to say about GlaxoSmithKline plc in its Q2 2021 investor letter:

” We sold our position in GlaxoSmithKline (tkr: GSK) due to disappointing failures with its Covid-19 vaccine and highly anticipated lung cancer drug, along with concerns regarding management, specifically the scientific leadership. GlaxoSmithKline is also spinning off its steady consumer segment, leaving the remaining company with its more volatile segments.”

Based on our calculations, GlaxoSmithKline plc (NYSE: GSK) was not able to clinch a spot in our list of the 30 Most Popular Stocks Among Hedge Funds. GSK was in 25 hedge fund portfolios at the end of the first quarter of 2021, compared to 30 funds in the fourth quarter of 2020. GlaxoSmithKline plc (NYSE: GSK) delivered a 7.40% return in the past 3 months.

Hedge funds’ reputation as shrewd investors has been tarnished in the last decade as their hedged returns couldn’t keep up with the unhedged returns of the market indices. Our research has shown that hedge funds’ small-cap stock picks managed to beat the market by double digits annually between 1999 and 2016, but the margin of outperformance has been declining in recent years. Nevertheless, we were still able to identify in advance a select group of hedge fund holdings that outperformed the S&P 500 ETFs by 115 percentage points since March 2017 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017. We have been tracking and sharing the list of these stocks since February 2017 in our quarterly newsletter.

At Insider Monkey, we scour multiple sources to uncover the next great investment idea. For example, lithium mining is one of the fastest growing industries right now, so we are checking out stock pitches like this emerging lithium stock. We go through lists like the 10 best EV stocks to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our homepage.

Disclosure: None. This article is originally published at Insider Monkey.